- Home
- LEG vs NRIX Comparison
LEG vs NRIX Comparison
Compare LEG & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEG
- NRIX
- Stock Information
- Founded
- LEG 1883
- NRIX 2009
- Country
- LEG United States
- NRIX United States
- Employees
- LEG N/A
- NRIX N/A
- Industry
- LEG Home Furnishings
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- LEG Consumer Discretionary
- NRIX Health Care
- Exchange
- LEG Nasdaq
- NRIX Nasdaq
- Market Cap
- LEG N/A
- NRIX 1.1B
- IPO Year
- LEG N/A
- NRIX 2020
- Fundamental
- Price
- LEG $7.93
- NRIX $11.88
- Analyst Decision
- LEG Hold
- NRIX Strong Buy
- Analyst Count
- LEG 3
- NRIX 17
- Target Price
- LEG $12.00
- NRIX $30.82
- AVG Volume (30 Days)
- LEG 3.5M
- NRIX 879.4K
- Earning Date
- LEG 04-29-2025
- NRIX 04-14-2025
- Dividend Yield
- LEG 2.53%
- NRIX N/A
- EPS Growth
- LEG N/A
- NRIX N/A
- EPS
- LEG N/A
- NRIX N/A
- Revenue
- LEG $4,383,600,000.00
- NRIX $54,549,000.00
- Revenue This Year
- LEG N/A
- NRIX N/A
- Revenue Next Year
- LEG $1.25
- NRIX $3.20
- P/E Ratio
- LEG N/A
- NRIX N/A
- Revenue Growth
- LEG N/A
- NRIX N/A
- 52 Week Low
- LEG $7.74
- NRIX $11.38
- 52 Week High
- LEG $19.33
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- LEG 35.87
- NRIX 29.28
- Support Level
- LEG $7.92
- NRIX $12.20
- Resistance Level
- LEG $8.21
- NRIX $13.10
- Average True Range (ATR)
- LEG 0.30
- NRIX 0.77
- MACD
- LEG 0.05
- NRIX -0.01
- Stochastic Oscillator
- LEG 8.70
- NRIX 14.33
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.